Monoclonal antibodies (MAbs) to ras, sis, erb-B, src, myb and myc oncoproteins were evaluated for their potential to target anti-cancer drugs to malignant cells. Each antibody was tested for reactivity against both fixed and viable cultured human tumour cells by immunofluorexence, and all reacted ag
ERBB oncogene proteins as targets for monoclonal antibodies
โ Scribed by O. L. Polanovski; E. N. Lebedenko; S. M. Deyev
- Book ID
- 111653696
- Publisher
- Springer
- Year
- 2012
- Tongue
- English
- Weight
- 658 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0006-2979
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
To develop an efficient strategy for the targeting of antitumor effector cells, we prepared bispecific antibody (BsAb) containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product. The prepared BsAb specifically reacts with both c-erb6-2positive tumor cells and CD3+ CTL. Human CD4' helper/killer
With the breast carcinoma cell line BT 474 used as a source of antigen, four rat monoclonal antibodies (MAbs) (3 IgG,, and I IgA) have been prepared against the external domain of the product of the c-erbB-2 proto-oncogene. All 4 antibodies stain frozen sections of tissues that over-express the prod